ReviewNature reviews. Cancer2010
Integrins in cancer: biological implications and therapeutic opportunities.
Review in Nature reviews. Cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1,885 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1,885 citing papers in PubMed, 3,680 citations in OpenAlex.
- Article
- Single-molecule force spectroscopy of ligand-receptor mechanics at extracellular vesicle biointerfaces.Journal of materials chemistry. B · 2026Article
- An Integrin β6-Targeted Antibody-Drug Conjugate Optimized for Intravesical Delivery to Treat Non-Muscle-Invasive Bladder Cancer.Molecular cancer therapeutics · 2026Article
- Shared ligand-blocking mechanism but distinct conformational modulation by α5-targeting antibodies BIIG2 and MINT1526A.Structure (London, England : 1993) · 2026Article
- Precisely Engineering Biomimetic Nanoparticles via Controlled Cell Membrane Coating.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Targeted delivery of peptidoglycan hydrolases (PGH) via engineered extracellular vesicles (EVs) to clear intracellular bacterial infections.Materials today. Bio · 2026Article
- Ectopic integrin β1 overproduction by squamous carcinoma cells contributes to immune evasion-associated metastasis.Cancer letters · 2026Article
- Synergistic Regulation of Tumor Immunity by Integrins and Lectins: From Molecular Mechanisms to Dual-Targeted Therapy.International journal of molecular sciences · 2026Review
- Engineering Nanotherapeutics Through Interfacial Mechanics: Mechanobiology and Precision Drug Delivery.Micromachines · 2026Article
- Integrin α2 (CD49b) blockade remodels the tumor immune microenvironment and enhances anti-PD-L1 therapy in 4T1 breast cancer model.Breast cancer research and treatment · 2026Article
- IGF2 knockout reduces but does not abolish osteosarcoma growth in vitro and in vivo.FEBS open bio · 2026Article
- Liquid biopsy in bladder cancer: towards precision oncology.Journal of translational medicine · 2026Review
- Curcumol Inhibits the Laminin-Facilitated Malignant Progression in Small-Cell Lung Cancer via Disrupting Laminin-Integrin β1 Interaction.Phytotherapy research : PTR · 2026Article
- Integrin α3Cancer pathogenesis and therapy · 2026Article
- Vitronectin Enrichment in Prostate Cancer Liver Metastases Promotes Adhesion and Survival.Cancer research communications · 2026Article
- Integrin-Defined Plasma Extracellular Vesicles for Early Breast Cancer Detection and Bone Metastasis Association.ACS applied nano materials · 2026Article
- Periostin drives psoriasis progression through the stimulation of cutaneous nerve fibers.iScience · 2026Article
- The Kallikrein-Kinin System: Proteolytic Orchestrators of Tissue Barrier Disruption in Inflammation and Cancer.International journal of molecular sciences · 2026Review
- Integrated bioinformatic and experimental analyses identify Lumican as a key regulator of LIPUS-induced osteogenesis through Integrin β1/FAK/ERK signaling.Molecular biology reports · 2026Article
- Beyond DNA damage: 3D tumor models and the integrin mechanobiology of radioresistance.Journal of experimental & clinical cancer research : CR · 2026Review
1,825 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The integrin family of cell adhesion receptors regulates a diverse array of cellular functions crucial to the initiation, progression and metastasis of solid tumours. The importance of integrins in several cell types that affect tumour progression has made them an appealing target for cancer therapy. Integrin antagonists, including the alphavbeta3 and alphavbeta5 inhibitor cilengitide, have shown encouraging activity in Phase II clinical trials and cilengitide is currently being tested in a Phase III trial in patients with glioblastoma. These exciting clinical developments emphasize the need to identify how integrin antagonists influence the tumour and its microenvironment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.